<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638468</url>
  </required_header>
  <id_info>
    <org_study_id>PERFUSE</org_study_id>
    <nct_id>NCT01638468</nct_id>
  </id_info>
  <brief_title>Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System</brief_title>
  <acronym>PERFUSE</acronym>
  <official_title>Pulmonary Embolism Removal With the AngioJet 6F Ultra SystEm (PERFUSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this European Post Market Follow-up Plan is designed to evaluate the safety,
      efficacy, adverse events and any new information that may surface regarding the use of the
      AngioJet Ultra PE Thrombectomy Catheter System in patients with thrombus in the main
      pulmonary and lobar arteries ≥ 6mm in diameter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite advances in prophylaxis, diagnostic modalities, and therapeutic options, pulmonary
      embolism remains a commonly under diagnosed and lethal entity. In the United States
      approximately 150,000 patients per year are diagnosed with acute pulmonary embolisms. Many
      additional deaths occur each year in the United States as a result of undiagnosed massive
      pulmonary embolisms. Taking these patients into account, it is thought that up to 600,000
      patients develop a pulmonary embolism annually in this country. In patients with acute
      pulmonary embolism, the most common cause of early death is right ventricular failure.

      In addition to anticoagulation therapy, several reperfusion therapies are being used to
      reverse right ventricular failure: systemic thrombolysis, surgical embolectomy, and catheter
      based therapy. Given the drawbacks of systemic thrombolytic therapy or surgical embolectomy,
      percutaneous catheter treatment is a reasonable alternative for patients with
      contraindications to systemic thrombolytic therapy or surgery. Current international
      consensus guidelines support the use of catheter interventions for selected pulmonary
      embolism patients at increased risk of adverse clinical outcomes.

      The AngioJet Ultra PE Thrombectomy catheter introduces a pressurized high velocity saline
      stream through a catheter tip so that the clot within a blood vessel is trapped, broken into
      small pieces and aspirated from the body.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Right Ventricular (RV) to Left Ventricular (LV) Ratio at 24 - 48 Hours as Measured by Echocardiography</measure>
    <time_frame>Baseline to 24-48 hours</time_frame>
    <description>The change in the subannular end-diastolic RV/LV ratio at 24-48 hrs following thrombectomy compared to baseline measurements as assessed by an independent core lab analysis. RV and LV values will be measured by echocardiography, a technique utilizing ultrasound waves to assess heart activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Percentage of patients with successful placement and operation of the AngioJet catheter in the pulmonary arteries during the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death - All Cause</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participant deaths due to any reason occurring within 3 months of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death - Cardiac Cause</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participant deaths due to cardiac causes occurring within 3 months of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Pulmonary Arterial Blood Pressure</measure>
    <time_frame>Baseline to Post Index Procedure</time_frame>
    <description>Change in systolic pulmonary arterial blood pressure at termination of the index procedure as compared to the pre-procedure assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Systolic Arterial Blood Pressure</measure>
    <time_frame>Post Index Procedure</time_frame>
    <description>Pulmonary systolic arterial blood pressure at termination of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Systolic Arterial Blood Pressure</measure>
    <time_frame>Baseline to Post Index Procedure</time_frame>
    <description>Change in systemic systolic arterial blood pressure at termination of the index procedure as compared to the pre-procedure assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Systolic Arterial Blood Pressure</measure>
    <time_frame>Post Index Procedure</time_frame>
    <description>Systemic systolic arterial blood pressure at termination of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>Baseline to Post Index Procedure</time_frame>
    <description>Change in heart rate at termination of the index procedure as compared to the pre-procedure assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Support</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Percentage of participants receiving vasopressor support during the index procedure. Vasopressor support are medications administered to prevent the narrowing of blood vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Related Adverse Event Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Number of procedure related adverse events occurring within 3 months of the index procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>AngioJet Ultra PE Thrombectomy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AngioJet Ultra PE Thrombectomy System</intervention_name>
    <description>Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
    <arm_group_label>AngioJet Ultra PE Thrombectomy System</arm_group_label>
    <other_name>AngioJet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic pulmonary embolism patients &gt;18 years

          2. Availability of a baseline contrast-enhanced chest computed tomogram or conventional
             pulmonary angiogram with evidence of pulmonary embolus in at least one main or lobar
             pulmonary artery ≥ 6mm in diameter

          3. Availability of a baseline transthoracic echocardiogram with sufficient image quality
             permitting the measurement of right ventricular (RV) and left ventricular (LV)
             dimensions in the apical or subcostal four-chamber view

          4. Echocardiographic evidence of right ventricular dilatation with a subannular RV/LV
             ratio ≥ 0.9 from the apical or subcostal four-chamber view

          5. Appropriate informed consent was obtained from the patient or legal representative

        Exclusion Criteria:

          1. Patient has underwent Cardiopulmonary Resuscitation (CPR) in the last 48 hours

          2. Patient is participating in any other clinical study

          3. Pregnancy, lactation or parturition within the previous 30 days (positive pregnancy
             test, women of childbearing age must be tested or use a medically accepted method of
             birth control)

          4. Inability to comply with study Follow-up assessments (e.g. due to geographic)

          5. Previous enrollment in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils Kucher, Prof Dr Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EO Ospedali Galliera - Genova</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Federico II di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant' Anna Di Como</name>
      <address>
        <city>San Fermo della Battaglia</city>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <results_first_submitted>September 12, 2016</results_first_submitted>
  <results_first_submitted_qc>September 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2016</results_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Acute Pulmonary Embolism</keyword>
  <keyword>Sub-massive Pulmonary Embolism</keyword>
  <keyword>Massive Pulmonary Embolism</keyword>
  <keyword>Pulmonary Thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AngioJet Ultra PE Thrombectomy System</title>
          <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AngioJet Ultra PE Thrombectomy System</title>
          <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.33" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.0" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.6" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Right Ventricular (RV) to Left Ventricular (LV) Ratio at 24 - 48 Hours as Measured by Echocardiography</title>
        <description>The change in the subannular end-diastolic RV/LV ratio at 24-48 hrs following thrombectomy compared to baseline measurements as assessed by an independent core lab analysis. RV and LV values will be measured by echocardiography, a technique utilizing ultrasound waves to assess heart activity.</description>
        <time_frame>Baseline to 24-48 hours</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular (RV) to Left Ventricular (LV) Ratio at 24 - 48 Hours as Measured by Echocardiography</title>
          <description>The change in the subannular end-diastolic RV/LV ratio at 24-48 hrs following thrombectomy compared to baseline measurements as assessed by an independent core lab analysis. RV and LV values will be measured by echocardiography, a technique utilizing ultrasound waves to assess heart activity.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.610" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Percentage of patients with successful placement and operation of the AngioJet catheter in the pulmonary arteries during the index procedure</description>
        <time_frame>Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Percentage of patients with successful placement and operation of the AngioJet catheter in the pulmonary arteries during the index procedure</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death - All Cause</title>
        <description>Number of participant deaths due to any reason occurring within 3 months of the index procedure.</description>
        <time_frame>3 months</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Death - All Cause</title>
          <description>Number of participant deaths due to any reason occurring within 3 months of the index procedure.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death - Cardiac Cause</title>
        <description>Number of participant deaths due to cardiac causes occurring within 3 months of the index procedure.</description>
        <time_frame>3 months</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Death - Cardiac Cause</title>
          <description>Number of participant deaths due to cardiac causes occurring within 3 months of the index procedure.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Pulmonary Arterial Blood Pressure</title>
        <description>Change in systolic pulmonary arterial blood pressure at termination of the index procedure as compared to the pre-procedure assessment.</description>
        <time_frame>Baseline to Post Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 1 participant was not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Pulmonary Arterial Blood Pressure</title>
          <description>Change in systolic pulmonary arterial blood pressure at termination of the index procedure as compared to the pre-procedure assessment.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 1 participant was not evaluable.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Systolic Arterial Blood Pressure</title>
        <description>Pulmonary systolic arterial blood pressure at termination of the index procedure.</description>
        <time_frame>Post Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 1 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Systolic Arterial Blood Pressure</title>
          <description>Pulmonary systolic arterial blood pressure at termination of the index procedure.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 1 participants were not evaluable.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systemic Systolic Arterial Blood Pressure</title>
        <description>Change in systemic systolic arterial blood pressure at termination of the index procedure as compared to the pre-procedure assessment.</description>
        <time_frame>Baseline to Post Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systemic Systolic Arterial Blood Pressure</title>
          <description>Change in systemic systolic arterial blood pressure at termination of the index procedure as compared to the pre-procedure assessment.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Systolic Arterial Blood Pressure</title>
        <description>Systemic systolic arterial blood pressure at termination of the index procedure.</description>
        <time_frame>Post Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Systolic Arterial Blood Pressure</title>
          <description>Systemic systolic arterial blood pressure at termination of the index procedure.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.0" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Heart Rate</title>
        <description>Change in heart rate at termination of the index procedure as compared to the pre-procedure assessment.</description>
        <time_frame>Baseline to Post Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 2 participants were not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate</title>
          <description>Change in heart rate at termination of the index procedure as compared to the pre-procedure assessment.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint; 2 participants were not evaluable.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor Support</title>
        <description>Percentage of participants receiving vasopressor support during the index procedure. Vasopressor support are medications administered to prevent the narrowing of blood vessels.</description>
        <time_frame>Index Procedure</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor Support</title>
          <description>Percentage of participants receiving vasopressor support during the index procedure. Vasopressor support are medications administered to prevent the narrowing of blood vessels.</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Related Adverse Event Rate</title>
        <description>Number of procedure related adverse events occurring within 3 months of the index procedure</description>
        <time_frame>3 months</time_frame>
        <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>AngioJet Ultra PE Thrombectomy System</title>
            <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Related Adverse Event Rate</title>
          <description>Number of procedure related adverse events occurring within 3 months of the index procedure</description>
          <population>Analysis was intention to treat; all participants in the study were to undergo clinical follow up to provide the information needed for this endpoint</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the index procedure through the 3 month follow up visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AngioJet Ultra PE Thrombectomy System</title>
          <description>Patients are treated with the AngioJet Ultra PE Thrombectomy System
AngioJet Ultra PE Thrombectomy System: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Macrohematuria (presence of blood cells in urine)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism, Re-occurring</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis (bleeding from the nose)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DeeAnn Tinjum</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>763-494-1927</phone>
      <email>deeann.tinjum@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

